Bristol Buy Hold or Sell Recommendation

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Considering the 30-days investment horizon, and your above-average risk tolerance our recommendation regarding Bristol Myers Squibb is 'Strong Hold'. Macroaxis provides Bristol Myers buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BMY positions. The advice algorithm takes into account all of Bristol Myers Squibb available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from BMY buy-and-hold perspective. Continue to Bristol Myers Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool.

Search Advice


Time Horizon

Risk Tolerance

Execute Advice
Sell Bristol MyersBuy Bristol Myers
Strong Hold


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Bristol Myers Squibb has a risk adjusted performance of (0.023406), jensen alpha of (0.1), total risk alpha of (0.17) and treynor ratio of (0.07)
Our buy, hold, or sell suggestions module provides unbiased buy, hold, or sell recommendation that can be used to complement current average analyst sentiment on Bristol Myers Squibb. Our buy, hold, or sell suggestions engine provides an advice for the firm potential to grow from the perspective of an investor's risk tolerance and investing horizon. To make sure Bristol Myers is not overpriced, please confirm all Bristol Myers Squibb fundamentals, including its price to earning, book value per share, current liabilities, as well as the relationship between the net income and beta . Given that Bristol Myers Squibb has a price to earning of 113.27 X, we suggest you to validate Bristol Myers Squibb market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Bristol Myers Trading Alerts and Improvement Suggestions

Bristol Myers Squibb generates negative expected return over the last 30 days
Over 79.0% of the company shares are held by institutions such as insurance companies
On 2nd of July 2020 Bristol Myers paid $ 0.45 per share dividend to its current shareholders

Bristol Myers current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bristol analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bristol analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Median Price73.00
Target Mean Price71.36
Recommendation Mean1.90
Target High Price81.00
Number Of Analyst Opinions11
Target Low Price62.00
Average Consensus Buy
The consensus estimates and target price estimation is comprised of individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Bristol Myers Returns Distribution Density

The chart of the probability distribution of Bristol Myers stock daily returns describes the distribution of returns around its average expected value. We use Bristol Myers Squibb' stock's Value At Risk and its Upside Potential as a relative measure of the distribution. The distribution of Bristol Myers returns is essential to provide solid investment advice for Bristol Myers stock.
Mean Return-0.02Value At Risk-1.9
Potential Upside2.04Standard Deviation1.43
 Return Density 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bristol Myers historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Bristol Myers Cash Flow Accounts

2014201520162017201820192020 (projected)
Capital Expenditure(526 M)(820 M)(1.22 B)(1.05 B)(951 M)(836 M)(902 M)
Depreciation Amortization and Accretion467 M376 M382 M789 M637 M1.75 B1.88 B
Net Cash Flow or Change in Cash and Cash Equivalents1.99 B(3.19 B)1.85 B1.18 B1.49 B5.91 B6.38 B
Net Cash Flow Business Acquisitions and Disposals3.37 B(403 M)975 M10 M3 M(8.78 B)(9.01 B)
Issuance Purchase of Equity Shares131 M288 M(231 M)(2.47 B)(320 M)(7.3 B)(7.49 B)
Issuance Repayment of Debt Securities(432 M)(1.14 B)110 M991 M(548 M)17.65 B19.05 B
Payment of Dividends and Other Cash Distributions(2.4 B)(2.48 B)(2.55 B)(2.58 B)(2.61 B)(2.68 B)(2.89 B)
Net Cash Flow from Financing(2.44 B)(3.62 B)(2.65 B)(4.08 B)(3.54 B)7.62 B8.22 B
Net Cash Flow from Investing1.22 B(1.57 B)1.48 B(66 M)(874 M)(9.77 B)(10.03 B)
Net Cash Flow Investment Acquisitions and Disposals(1.62 B)(349 M)1.72 B979 M74 M(152 M)(164 M)
Net Cash Flow from Operations3.15 B2.1 B3.06 B5.28 B5.94 B8.07 B6.96 B
Effect of Exchange Rate Changes on Cash58 M(95 M)(33 M)52 M(41 M)(9 M)(9.24 M)
Share Based Compensation213 M235 M205 M199 M221 M441 M358.21 M

Bristol Myers Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bristol Myers or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bristol Myers stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bristol stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW=0.38
Overall volatility
Information ratio =-0.15

Bristol Myers Volatility Alert

Bristol Myers Squibb exhibits very low volatility with skewness of -0.68 and kurtosis of 3.12. However, we advise investors to further study Bristol Myers Squibb technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Bristol Myers to competition

Bristol Myers Fundamental Vs Peers

FundamentalsBristol MyersPeer Average
Return On Equity3.00 %(0.31) %
Return On Asset5.82 %(0.14) %
Profit Margin3.08 %(1.27) %
Operating Margin37.35 %(5.51) %
Current Valuation164.04 B16.62 B
Shares Outstanding2.26 B571.82 M
Shares Owned by Insiders0.11 %10.09 %
Shares Owned by Institutions79.09 %39.21 %
Number of Shares Shorted30.59 M4.71 M
Price to Earning113.27 X28.72 X
Price to Book2.63 X9.51 X
Price to Sales4.24 X11.42 X
Revenue31.01 B9.43 B
Gross Profit18.93 B27.38 B
EBITDA11.58 B3.9 B
Net Income954 M570.98 M
Cash and Equivalents18.32 B2.7 B
Cash per Share8.10 X5.01 X
Total Debt47.53 B5.32 B
Debt to Equity0.95 %48.70 %
Current Ratio1.66 X2.16 X
Book Value Per Share22.06 X1.93 K
Cash Flow from Operations10.57 B971.22 M
Short Ratio1.88 X4.00 X
Earnings Per Share0.51 X3.12 X
Price to Earnings To Growth0.44 X4.89 X
Number of Employees30 K18.84 K
Market Capitalization131.48 B19.03 B
Total Asset31.75 B29.47 B
Retained Earnings37.01 B9.33 B
Working Capital2.4 B1.48 B
Current Asset10.41 B9.34 B
   Payment of 4463 shares by Samit Hirawat of Bristol Myers subject to Rule 16b-3 [view details]

Bristol Myers Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bristol . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution124003.476764
Daily Balance Of Power0.1707
Rate Of Daily Change1.002424
Day Median Price57.69
Day Typical Price57.756667
Market Facilitation Index0.0
Price Action Indicator0.27

About Bristol Myers Buy or Sell Advice

When is the right time to buy or sell Bristol Myers Squibb? Buying stocks such as Bristol Myers isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily bases. Although Bristol Myers investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply. Please read more on our stock advisor page.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B

Did You Try This Idea?

Run Dividend Beast Thematic Idea Now

Dividend Beast
Dividend Beast Theme
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. Dividend Beast theme has 58 constituents.
View All  Next Launch Dividend Beast
Continue to Bristol Myers Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page